Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

• Katja Sockel,
• Martin Bornhaeuser,
• Eva Mischak-Weissinger,
• Rudolf Trenschel,
• Martin Wermke,
• Christian Unzicker,
• Guido Kobbe,
• Jürgen Finke,
• Ulrich Germing,
• Brigitte Mohr,
• Jochen Greiner,
• Dietrich Beelen,
• Christian Thiede,
• Gerhard Ehninger,
• Uwe Platzbecker

Affiliations

Katja Sockel

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany

Martin Bornhaeuser

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany

Eva Mischak-Weissinger

2Department of Hematology/Oncology, Hannover Medical School, Germany

Rudolf Trenschel

3Department of Bone Marrow Transplantation, University Hospital Essen, Germany

Martin Wermke

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany

Christian Unzicker

4Department of Internal Medicine II, Wuerzburg University Medical Center, Germany

Guido Kobbe

5Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Düsseldorf, Germany

Jürgen Finke

6Department of Medicine 1, Hematology/Oncology, University Hospital Freiburg, Germany

Ulrich Germing

5Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Düsseldorf, Germany

Brigitte Mohr

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany

Jochen Greiner

7Department of Internal Medicine III, University of Ulm, Germany

Dietrich Beelen

3Department of Bone Marrow Transplantation, University Hospital Essen, Germany

Christian Thiede

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany

Gerhard Ehninger

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany

Uwe Platzbecker

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany